1887

Journal of Medical Microbiology logo

Volume 62, Issue 9

Carbapenem-resistance mechanisms of multidrug-resistant Free

Abstract

Clonal dissemination of multidrug-resistant (MDRPA) is a major concern worldwide. The aim of this study was to explore the mechanisms leading to the carbapenem resistance of an MDRPA clone. Isolates were obtained from a surgical wound, sputum, urine and a blood culture. Pulsed-field gel electrophoresis (PFGE) showed high genomic homogeneity of these isolates and confirmed the circulation of an endemic clone belonging to serotype O4. Outer membrane protein (OMP) bands were visualized by SDS-PAGE, meropenem accumulation was measured in a bioassay and integrons were detected by PCR. Efflux pumps were studied for several antimicrobial agents and synergic combinations thereof in the presence or absence of both carbonyl cyanide -chlorophenylhydrazone (CCCP) and Phe-Arg-β-naphthylamide (PAβN) at final concentrations of 10 and 40 mg l, respectively. On OMP electrophoretic profiles, MDRPA showed a reduction of outer membrane porin D (OprD) and PCR demonstrated the presence of a class 1 integron with a cassette encoding aminoglycoside adenyltransferase B (). Meropenem accumulation was slightly higher in bacilli than in the filamentous cells that formed in the presence of antibiotics. Overexpression of the efflux pump MexAB-OprM and a functional MexXY-OprM were detected in all isolates.

  • Received:
  • Accepted:
  • Published Online:
© 2013 SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.058354-0
2013-09-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/9/1317.html?itemId=/content/journal/jmm/10.1099/jmm.0.058354-0&mimeType=html&fmt=ahah

References

  1. Azucena E., Mobashery S. 2001; Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat 4:106–117 [View Article][PubMed]
     [Google Scholar]
  2. Blumer J. L., Saiman L., Konstan M. W., Melnick D. 2005; The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128:2336–2346 [View Article][PubMed]
     [Google Scholar]
  3. Cabot G., Ocampo-Sosa A. A., Domínguez M. A., Gago J. F., Juan C., Tubau F., Rodríguez C., Moyà B., Peña C. other authors 2012; Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 56:6349–6357 [View Article][PubMed]
     [Google Scholar]
  4. Chen J., Su Z., Liu Y., Wang S., Dai X., Li Y., Peng S., Shao Q., Zhang H. other authors 2009; Identification and characterization of class 1 integrons among Pseudomonas aeruginosa isolates from patients in Zhenjiang, China. Int J Infect Dis 13:717–721 [View Article][PubMed]
     [Google Scholar]
  5. CLSI 2010; Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute;
     [Google Scholar]
  6. Drusano G. L., Liu W., Fregeau C., Kulawy R., Louie A. 2009; Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53:2266–2273 [View Article][PubMed]
     [Google Scholar]
  7. EUCAST 2011; European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. http://www.eucast.org
  8. Falagas M. E., Koletsi P. K., Bliziotis I. A. 2006; The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. . J Med Microbiol 55:1619–1629 [View Article][PubMed]
     [Google Scholar]
  9. Farra A., Islam S., Strålfors A., Sörberg M., Wretlind B. 2008; Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents 31:427–433 [View Article][PubMed]
     [Google Scholar]
  10. Fenosa A., Fusté E., Ruiz L., Veiga-Crespo P., Vinuesa T., Guallar V., Villa T. G., Viñas M. 2009; Role of TolC in Klebsiella oxytoca resistance to antibiotics. J Antimicrob Chemother 63:668–674 [View Article][PubMed]
     [Google Scholar]
  11. Fonseca E. L., Vieira V. V., Cipriano R., Vicente A. C. 2005; Class 1 integrons in Pseudomonas aeruginosa isolates from clinical settings in Amazon region, Brazil. FEMS Immunol Med Microbiol 44:303–309 [View Article][PubMed]
     [Google Scholar]
  12. Horii T., Ichiyama S., Ohta M., Kobayashi M. 1999; Relationship between morphological changes and endotoxin release induced by carbapenems in Pseudomonas aeruginosa. . J Med Microbiol 48:309–315 [View Article][PubMed]
     [Google Scholar]
  13. Ikonomidis A., Tsakris A., Kantzanou M., Spanakis N., Maniatis A. N., Pournaras S. 2008; Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol Lett 279:36–39 [View Article][PubMed]
     [Google Scholar]
  14. Kanj S. S., Kanafani Z. A. 2011; Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. . Mayo Clin Proc 86:250–259 [View Article][PubMed]
     [Google Scholar]
  15. Koutsogiannou M., Drougka E., Liakopoulos A., Jelastopulu E., Petinaki E., Anastassiou E. D., Spiliopoulou I., Christofidou M. 2013; Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. J Clin Microbiol 51:665–668 [View Article][PubMed]
     [Google Scholar]
  16. Kriengkauykiat J., Porter E., Lomovskaya O., Wong-Beringer A. 2005; Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. . Antimicrob Agents Chemother 49:565–570 [View Article][PubMed]
     [Google Scholar]
  17. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [View Article][PubMed]
     [Google Scholar]
  18. Lévesque C., Piché L., Larose C., Roy P. H. 1995; PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob Agents Chemother 39:185–191 [View Article][PubMed]
     [Google Scholar]
  19. Llanes C., Neuwirth C., El Garch F., Hocquet D., Plésiat P. 2006; Genetic analysis of a multiresistant strain of Pseudomonas aeruginosa producing PER-1 beta-lactamase. Clin Microbiol Infect 12:270–278 [View Article][PubMed]
     [Google Scholar]
  20. Lomovskaya O., Watkins W. 2001; Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 3:225–236[PubMed]
     [Google Scholar]
  21. Mao W., Warren M. S., Lee A., Mistry A., Lomovskaya O. 2001; MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. . Antimicrob Agents Chemother 45:2001–2007 [View Article][PubMed]
     [Google Scholar]
  22. Maslow J. N., Slutsky A. M., Arbeit R. D. 1993; Application of pulsed-field gel electrophoresis to molecular epidemiology. In Diagnostic Molecular Microbiology: Principles and Applications pp. 563–572 Edited by Persing D. H., Smith T. F., Tenover F. C., White T. J. Washington, DC: American Society for Microbiology;
     [Google Scholar]
  23. Morita Y., Tomida J., Kawamura Y. 2012; MexXY multidrug efflux system of Pseudomonas aeruginosa. . Front Microbiol 3:408 [View Article][PubMed]
     [Google Scholar]
  24. Nakajima A., Sugimoto Y., Yoneyama H., Nakae T. 2002; High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 46:391–395[PubMed] [CrossRef]
     [Google Scholar]
  25. Nemec A., Krizova L., Maixnerova M., Musilek M. 2010; Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic. Res Microbiol 161:234–242 [View Article][PubMed]
     [Google Scholar]
  26. Nicolau D. P. 2008; Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 9:23–37 [View Article][PubMed]
     [Google Scholar]
  27. Nikaido H. 1998; Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 27:Suppl 1S32–S41 [View Article][PubMed]
     [Google Scholar]
  28. Pagès J. M., Masi M., Barbe J. 2005; Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 11:382–389 [View Article][PubMed]
     [Google Scholar]
  29. Poole K. 2004; Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect 10:12–26 [View Article][PubMed]
     [Google Scholar]
  30. Puig M., Fusté C., Viñas M. 1993; Outer membrane proteins from Serratia marcescens. . Can J Microbiol 39:108–111 [View Article][PubMed]
     [Google Scholar]
  31. Rodriguez N., Roig S., Olmedo N., Lorén J. G., Rius N. 2004; A new bioassay method for quantitative analysis of tetracyclines. J Ind Microbiol Biotechnol 31:379–383 [View Article][PubMed]
     [Google Scholar]
  32. Rodríguez-Martínez J. M., Poirel L., Nordmann P. 2009; Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. . Antimicrob Agents Chemother 53:4783–4788 [View Article][PubMed]
     [Google Scholar]
  33. Ruiz-Martínez L., López-Jiménez L., Fusté E., Vinuesa T., Martínez J. P., Viñas M. 2011; Class 1 integrons in environmental and clinical isolates of Pseudomonas aeruginosa. . Int J Antimicrob Agents 38:398–402 [View Article][PubMed]
     [Google Scholar]
  34. Shahcheraghi F., Badmasti F., Feizabadi M. M. 2010; Molecular characterization of class 1 integrons in MDR Pseudomonas aeruginosa isolated from clinical settings in Iran, Tehran. FEMS Immunol Med Microbiol 58:421–425[PubMed]
     [Google Scholar]
  35. Strateva T., Yordanov D. 2009; Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 58:1133–1148 [View Article][PubMed]
     [Google Scholar]
  36. Syrmis M., Bell S., Bye P., Coulter C., Harbour C., Iredell J., Kidd T., O’Carroll M., Rose B. other authors 2008; High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. Pathology 40:524–525 [View Article][PubMed]
     [Google Scholar]
  37. Trautmann M., Heinemann M., Zick R., Möricke A., Seidelmann M., Berger D. 1998; Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis 17:754–760 [View Article][PubMed]
     [Google Scholar]
  38. Veiga-Crespo P., Fusté E., Vinuesa T., Viñas M., Villa T. G. 2011; Synergism between outer membrane proteins and antimicrobials. Antimicrob Agents Chemother 55:2206–2211 [View Article][PubMed]
     [Google Scholar]
  39. Weiss D. S., Chen J. C., Ghigo J. M., Boyd D., Beckwith J. 1999; Localization of FtsI (PBP3) to the septal ring requires its membrane anchor, the Z ring, FtsA, FtsQ, and FtsL. J Bacteriol 181:508–520[PubMed]
     [Google Scholar]
  40. Woodford N., Turton J. F., Livermore D. M. 2011; Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 35:736–755 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.058354-0
Loading
Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa
J. Med. Microbiol. 62, 1317 (2013); https://doi.org/10.1099/jmm.0.058354-0
/content/journal/jmm/10.1099/jmm.0.058354-0
/content/journal/jmm/10.1099/jmm.0.058354-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error